M&A Deal Summary

ProKidney Acquires inRegen

On January 14, 2019, ProKidney acquired life science company inRegen for 62M USD

Acquisition Highlights
  • This is ProKidney’s 1st transaction in the Life Science sector.
  • This is ProKidney’s largest (disclosed) transaction.
  • This is ProKidney’s 1st transaction in the United States.
  • This is ProKidney’s 1st transaction in New York.

M&A Deal Summary
Date 2019-01-14
Target inRegen
Sector Life Science
Buyer(s) ProKidney
Deal Type Add-on Acquisition
Deal Value 62M USD

Target

inRegen

New York, United States
inRegen is a biotechnology company focused on developing advanced cellular therapies for treating chronic kidney disease (CKD). The company is based on over 14 years of proprietary breakthroughs in progenitor cell biology research, development, and manufacturing. It produces a personalized autologous cell therapy, by using the patient's own cells and proprietary methods of manufacturing.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ProKidney

New York, New York, United States
Category Company
Sector Life Science
DESCRIPTION

ProKidney LLC is a biotechnology company founded by a group of investors led by Pablo Legorreta.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal